抗癌药物药物化学第二版 1849条(本栏目收费,不能显示细节,电话15274084725)
3.2.2. Irreversible inhibitors of glutathione S-transferase ... 672 672
Alvespimycin, 553–554 554
Alvocidib (flavopiridol), 435, 436f 436
Amifostine, 182–183, 183f 183
9-Aminocamptothecin, 294 294
5-Aminolevulinic acid (ALA, Levulan®), 187, 187f, 709 709
Aminopeptidase N (APN, CD13), 514 514
Aminopeptidase N (CD13), 645 645
2.6. Other monofunctional intercalating agents ... 282 282
3. Bifunctional intercalating agents .....282 282
4. Indirect DNA damage by DNA topoisomerase inhibitors ...285 285
4.1. Topoisomerase I mechanism ..... 285 285
4.2. Topoisomerase II mechanism .... 286 286
5. Specific topoisomerase I inhibitors .....290 290
5.1. Camptothecins .... 290 290
5.2. Non-camptothecin topoisomerase I inhibitors ... 298 298
6. Topoisomerase II poisons .....301 301
6.1. Acridine derivatives .... 301 301
6.2. Anthracyclines and related compounds .... 302 302
6.3. Non-intercalating topoisomerase II poisons .... 305 305
6.3.1. Etoposide and its analogs .... 305 305
6.3.2. Salvicine .... 308 308
7. Topoisomerase II catalytic inhibitors .....309 309
7.1. Inhibitors of the binding of topoisomerase II to DNA ... 309 309
7.1.1. Aclarubicin .... 309 309
7.1.2. Merbarone ..... 310 310
7.1.3. Bis(dioxopiperazines) .... 310 310
8. Telomerase inhibitors and other anticancer approaches targeting telomeres ...311 311